About Fogpharma
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Open positions (1)
Company details
Funding
Total raised
$836M
Last stage
Series F
Investors
Founders
Gregory Verdine
Harvard professor and serial biotech entrepreneur who spun FogPharma out of his Harvard lab in 2016. Pioneer in 'drugging the undruggable' and inventor of stapled peptide technology.
LinkedInJohn McGee
Co-founded FogPharma in 2015 alongside Greg Verdine; led and evolved the company's core innovative experimental platform.
Weiqing Zhou
Co-founder and company-builder at FogPharma from its founding in December 2015; described by Greg Verdine as an 'extraordinarily talented entrepreneur and company-builder'.
Sir David Lane
Renowned scientist and co-founder of Parabilis Medicines; also noted as Founder and Chief Scientist of Altos Labs, Inc.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.